Carter Barger, PhD

Title(s)Postdoctoral Scholar, Neurological Surgery
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Nebraska Medical Center, Omaha, NEPhD2018Cancer Biology
    Rush University, Chicago, ILMS2008Clinical Laboratory Sciences
    University of Iowa, Iowa City, IABS2005Microbiology

    Collapse Research 
    Collapse Research Activities and Funding
    FOXM1-RHNO1 Oncogenic Axis in Ovarian Cancer
    NIH/NCI K00CA212470Aug 1, 2018 - Jul 31, 2022
    Role: Principal Investigator
    FOXM1-RHNO1 Oncogenic Axis in Ovarian Cancer
    NIH/NCI F99CA212470Sep 21, 2016 - Aug 31, 2018
    Role: Principal Investigator
    Forkhead Box M1 (FOXM1) in High Grade Serous Ovarian Cancer
    University of Nebraska University of Nebraska Presidential Graduate FelloAug 1, 2016 - Jul 31, 2017
    Role: Principal Investigator
    Forkhead Box M1 (FOXM1) in High Grade Serous Ovarian Cancer
    University of Nebraska Medical Center UNMC Program of Excellence FellowshipAug 1, 2015 - Jul 31, 2016
    Role: Principal Investigator
    Cancer Biology Training Program
    NIH/NCI T32CA009476Jun 1, 2013 - May 31, 2014
    Role: Trainee

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Barger CJ, Zhang W, Sharma A, Chee L, James SR, Kufel CN, Miller A, Meza J, Drapkin R, Odunsi K, Klinkebiel D, Karpf AR. Expression of the POTE gene family in human ovarian cancer. Sci Rep. 2018 Nov 20; 8(1):17136. PMID: 30459449.
      View in: PubMed
    2. Robb CM, Kour S, Contreras JI, Agarwal E, Barger CJ, Rana S, Sonawane Y, Neilsen BK, Taylor M, Kizhake S, Thakare RN, Chowdhury S, Wang J, Black JD, Hollingsworth MA, Brattain MG, Natarajan A. Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget. 2018 Jan 12; 9(4):5216-5232. PMID: 29435174.
      View in: PubMed
    3. Zhang W, Barger CJ, Eng KH, Klinkebiel D, Link PA, Omilian A, Bshara W, Odunsi K, Karpf AR. PRAME expression and promoter hypomethylation in epithelial ovarian cancer. Oncotarget. 2016 Jul 19; 7(29):45352-45369. PMID: 27322684.
      View in: PubMed
    4. Lum MA, Barger CJ, Hsu AH, Leontieva OV, Black AR, Black JD. Protein Kinase Ca (PKCa) Is Resistant to Long Term Desensitization/Down-regulation by Prolonged Diacylglycerol Stimulation. J Biol Chem. 2016 Mar 18; 291(12):6331-46. PMID: 26769967.
      View in: PubMed
    5. Barger CJ, Zhang W, Hillman J, Stablewski AB, Higgins MJ, Vanderhyden BC, Odunsi K, Karpf AR. Genetic determinants of FOXM1 overexpression in epithelial ovarian cancer and functional contribution to cell cycle progression. Oncotarget. 2015 Sep 29; 6(29):27613-27. PMID: 26243836; PMCID: PMC4695012.
    6. Zhang W, Barger CJ, Link PA, Mhawech-Fauceglia P, Miller A, Akers SN, Odunsi K, Karpf AR. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer. Epigenetics. 2015; 10(8):736-48. PMID: 26098711; PMCID: PMC4622579.
    7. Buckingham L, Penfield Faber L, Kim A, Liptay M, Barger C, Basu S, Fidler M, Walters K, Bonomi P, Coon J. PTEN, RASSF1 and DAPK site-specific hypermethylation and outcome in surgically treated stage I and II nonsmall cell lung cancer patients. Int J Cancer. 2010 Apr 01; 126(7):1630-9. PMID: 19795445.
      View in: PubMed